Actively Recruiting
A Double-Blind, Randomized Study Comparing Inhaled Staccato Alprazolam to Placebo for Treating Stereotypical Prolonged Seizures in People 12 Years and Older
Led by UCB Biopharma SRL · Updated on 2026-10-26
350
Participants Needed
183
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of Staccato alprazolam, an inhaled medication, in people aged 12 years and older who experience stereotypical prolonged seizures. The study aims to compare a single dose of Staccato alprazolam with a placebo in quickly stopping a seizure within 90 seconds and preventing further seizures for up to 2 hours after treatment. Participants are randomly assigned to receive either one dose of Staccato alprazolam or a matching placebo by inhalation in this double-blind study. This single-dose treatment is given during the outpatient treatment period, and participants are monitored closely to assess seizure control and safety. During the study, participants will have their seizures evaluated for treatment success within 90 seconds and for any recurrence up to 6 hours after dosing. Researchers will also monitor respiratory events and seizure frequency. Participants will have regular assessments, including safety follow-up visits extending up to 19 weeks after treatment, to ensure thorough monitoring of effects and any adverse events.
CONDITIONS
Brief Title
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Research Team
U
UCB Cares
U
UCB Cares
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here